Tirzepatide Pre-mixed Pen 40/20mg

Tirzepatide Dual GIP/GLP-1 Receptor Agonist

Tirzepatide is a synthetic 39-amino acid linear peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is engineered with a C20 fatty diacid chain attached via a linker for prolonged half-life and once-weekly dosing.

Key Characteristics:

• Structure: Modified GIP sequence with GLP-1 receptor co-agonism and lipidation for extended pharmacokinetics

• Mechanism: Simultaneous activation of GIP and GLP-1 receptors enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral pathways

• Potency: Balanced dual agonism with greater affinity for GIP receptor than native GIP, resulting in superior metabolic effects compared to single GLP-1 agonists

• Half-life: Approximately 5 days, enabling once-weekly administration

Research Applications:

• Type 2 diabetes mellitus and glycemic control studies

• Obesity and weight management research

• Metabolic syndrome and insulin resistance models

• Cardiovascular and renal outcomes in metabolic disease

• Non-alcoholic fatty liver disease (NAFLD/NASH) investigations

• Appetite regulation and energy balance studies

Tirzepatide is notable for producing unprecedented weight loss and glycemic improvements in clinical research, attributed to the synergistic effects of dual GIP/GLP-1 receptor activation. It represents a significant advancement in incretin-based therapies for metabolic disorders.

For laboratory research use only. Not intended for human or veterinary use.